Literature DB >> 8137250

Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.

E L Schwartz1, N Baptiste, C J O'Connor, S Wadler, B A Otter.   

Abstract

alpha-Interferon (IFN alpha) potentiates the cytotoxicity of 5-fluorouracil (FUra) in vitro, and the combination has clinical efficacy in advanced colorectal cancer. We have reported previously an IFN alpha-mediated elevation in cellular FdUMP levels accompanied by the stimulation of thymidine phosphorylase (TP) activity in extracts from HT-29 human colon carcinoma cells treated with IFN alpha. We have now found that this effect of IFN alpha can be measured in vivo as an increase in thymine incorporation in intact cells. The increase was only 3-fold, however, compared to the 12-fold increase seen in TP activity in cell extracts. This suggested that the cosubstrate for TP, deoxyribose-1-phosphate, was rate limiting in the cells. Since the synthetic pathway of TP can also proceed via a transferase reaction, natural and modified deoxyribonucleosides were tested as deoxyribosyl donors. TP activity was measurable in cell extracts using deoxyinosine as cosubstrate with either thymine or FUra, although activity was only 10% of that measured with deoxyribose-1-phosphate. The pyrimidine analogue 5-propynyloxy-2'-deoxyuridine (PO-dUrd) had 15% of the maximal TP activity in cell extracts and also increased thymine incorporation in intact cells 10-fold. Both 2'-deoxyinosine and PO-dUrd potentiated the cytotoxicity of FUra by 8-11-fold. IFN alpha potentiated the cytotoxicity of FUra by 1.8-fold, and the combination of IFN alpha and PO-dUrd produced a 25-fold increase in the cytotoxicity of FUra. Neither the corresponding analogue riboside, 5-propynyloxyuridine, nor the analogue base, 5-propynyloxyuracil, had any effect on FUra cytotoxicity. There was a significant correlation between the ability of a nucleoside and/or IFN alpha combination to increase thymine incorporation and to reduce the 50% inhibitory concentration for FUra. IFN alpha and PO-dUrd also potentiated the inhibition by FUra of thymidylate synthase activity. These findings suggest that the use of a deoxyribonucleoside to provide the rate limiting cosubstrate would complement the stimulation of TP by IFN alpha, and together they should further enhance the antitumor activity of FUra.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137250

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 2.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

3.  Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells.

Authors:  Yongxue Yao; Toshihiko Kubota; Kazufumi Sato; Hiroaki Takeuchi; Ryuhei Kitai; Shigeru Matsukawa
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

4.  Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.

Authors:  Raphaelle Fanciullino; Sarah Giacometti; Claude Aubert; Frederic Fina; Pierre-Marie Martin; Philippe Piccerelle; Joseph Ciccolini
Journal:  Pharm Res       Date:  2005-10-21       Impact factor: 4.200

5.  Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance.

Authors:  Michal Stark; Eran E Bram; Martin Akerman; Yael Mandel-Gutfreund; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

Review 6.  Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

Authors:  M I Koukourakis; A Giatromanolaki; K J O'Byrne; M Comley; R M Whitehouse; D C Talbot; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.

Authors:  J P Braybrooke; D J Propper; K J O'Byrne; M I Koukourakis; A V Patterson; S Houlbrook; S D Love; S Varcoe; M Taylor; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

9.  Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.

Authors:  M I Koukourakis; A Giatromanolaki; S Kakolyris; K J O'Byrne; N Apostolikas; J Skarlatos; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

10.  Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

Authors:  A V Patterson; H Zhang; A Moghaddam; R Bicknell; D C Talbot; I J Stratford; A L Harris
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.